PPP2R1A missense mutations as a novel biomarker of response to ATR inhibitors in ARID1A mutant ovarian clear cell carcinoma. (October 2022) - Stewart, J.; Baxter, J.; Zatreanu, D.; Brough, R.; Song, F.; Konde, A.; Krastev, D.; Alexander, J.; Natrajan, R.; Banerjee, S.; Stephen, P.; Lord, C.